Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/disease-modifying-agents-for-multiple-sclerosis-RgWKR5ndeg
References (295)
-
J. Antel, A. Bar-Or (2006)
Roles of immunoglobulins and B cells in multiple sclerosis: From pathogenesis to treatmentJournal of Neuroimmunology, 180
-
Marcel Brisebois, S. Zehntner, José Estrada, T. Owens, S. Fournier (2006)
A Pathogenic Role for CD8+ T Cells in a Spontaneous Model of Demyelinating Disease1The Journal of Immunology, 177
-
B. Cree, S. Lamb, K. Morgan, A. Chen, E. Waubant, C. Genain (2005)
An open label study of the effects of rituximab in neuromyelitis opticaNeurology, 64
-
KP Johnson, BR Brooks, JA Cohen (1995)
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trialCopolymer 1 Multiple Sclerosis Study Group. Neurology, 45
-
G. Ciancio, G. Burke, K. Suzart, A. Vaidya, D. Roth, W. Kupin, A. Mattiazzi, A. Rosen, V. Esquenazi, Joshua Miller (2003)
Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.Transplantation proceedings, 35 2
-
S. Dillon, J. Gross, S. Ansell, A. Novak (2006)
An APRIL to remember: novel TNF ligands as therapeutic targetsNature Reviews Drug Discovery, 5
-
O. Aktas, S. Waiczies, A. Smorodchenko, J. Dörr, Bibiane Seeger, T. Prozorovski, Stephanie Sallach, M. Endres, S. Brocke, R. Nitsch, F. Zipp (2003)
Treatment of Relapsing Paralysis in Experimental Encephalomyelitis by Targeting Th1 Cells through AtorvastatinThe Journal of Experimental Medicine, 197
-
GP Rice, M Filippi, G Comi (2000)
Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trialCladribine MRI Study Group. Neurology, 54
-
C. Lucchinetti, W. Brück, J. Parisi, B. Scheithauer, Moses Rodriguez, H. Lassmann (2000)
Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelinationAnnals of Neurology, 47
-
O. Neuhaus, J. Archelos, H. Hartung (2003)
Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection.Trends in pharmacological sciences, 24 3
-
E. Huseby, D. Liggitt, T. Brabb, Bryan Schnabel, Claes Öhlén, J. Goverman (2001)
A Pathogenic Role for Myelin-Specific Cd8+ T Cells in a Model for Multiple SclerosisThe Journal of Experimental Medicine, 194
-
F. Gay, T. Drye, G. Dick, M. Esiri (1997)
The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion.Brain : a journal of neurology, 120 ( Pt 8)
-
M. Juryńczyk, A. Jurewicz, B. Bielecki, C. Raine, K. Selmaj (2008)
Overcoming failure to repair demyelination in EAE: γ-secretase inhibition of Notch signalingJournal of the Neurological Sciences, 265
-
M. Juryńczyk, A. Jurewicz, B. Bielecki, C. Raine, K. Selmaj (2005)
Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosisJournal of Neuroimmunology, 170
-
Martin Weber, T. Prod'homme, S. Youssef, S. Dunn, Cynthia Rundle, Linda Lee, J. Patarroyo, O. Stüve, R. Sobel, L. Steinman, S. Zamvil (2007)
Type II monocytes modulate T cell–mediated central nervous system autoimmune diseaseNature Medicine, 13
-
S. Stohlman, D. Hinton (2001)
Viral Induced DemyelinationBrain Pathology, 11
-
A. Cross, J. Stark, Joanne Lauber, Michael Ramsbottom, J. Lyons (2006)
Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 180
-
F. Paul, S. Waiczies, J. Wuerfel, J. Bellmann-Strobl, J. Dörr, H. Waiczies, M. Haertle, K. Wernecke, H. Volk, O. Aktas, F. Zipp (2008)
Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple SclerosisPLoS ONE, 3
-
N. Monson, P. Cravens, E. Frohman, Kathleen Hawker, M. Racke (2005)
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.Archives of neurology, 62 2
-
K. Yonekawa, J. Harlan (2005)
Targeting leukocyte integrins in human diseasesJournal of Leukocyte Biology, 77
-
R. Magliozzi, Sandra Columba-cabezas, B. Serafini, F. Aloisi (2004)
Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitisJournal of Neuroimmunology, 148
-
D. Paty, D. Li (1993)
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 43
-
G. Ebers (1998)
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisThe Lancet, 352
-
H. Hartung, B. Kieseier (2000)
The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous systemJournal of Neuroimmunology, 107
-
B. Imbimbo (2008)
Therapeutic Potential of γ -Secretase Inhibitors and ModulatorsCurrent Topics in Medicinal Chemistry, 8
-
R. Kapoor (2006)
Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial designCurrent Opinion in Neurology, 19
-
B. Cannella, C. Raine (2004)
Multiple sclerosis: Cytokine receptors on oligodendrocytes predict innate regulationAnnals of Neurology, 55
-
S. Sawcer, H. Jones, R. Feakes, J. Gray, Niki Smaldon, J. Chataway, N. Robertson, D. Clayton, P. Goodfellow, Alastair Compston (1996)
A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22Nature Genetics, 13
-
N. Sicotte, S. Liva, Rochelle Klutch, Paul Pfeiffer, Seth Bouvier, S. Odesa, T. Wu, R. Voskuhl (2002)
Treatment of multiple sclerosis with the pregnancy hormone estriolAnnals of Neurology, 52
-
J. Rose, J. Burns, J. Bjorklund, J. Klein, H. Watt, N. Carlson (2007)
Daclizumab phase II trial in relapsing and remitting multiple sclerosisNeurology, 69
-
JH Noseworthy, C Lucchinetti, M Rodriguez (2000)
Multiple sclerosisN Engl J Med, 343
-
S. Nessler, C. Stadelmann, A. Bittner, Kerstin Schlegel, Felix Gronen, W. Brueck, B. Hemmer, N. Sommer (2006)
Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist — A putative role for substance P in CNS inflammationJournal of Neuroimmunology, 179
-
Esther Byun, S. Caillier, X. Montalban, P. Villoslada, Ó. Fernández, D. Brassat, M. Comabella, Joanne Wang, L. Barcellos, S. Baranzini, J. Oksenberg (2008)
Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.Archives of neurology, 65 3
-
G. Comi, M. Filippi (2005)
Clinical trials in multiple sclerosis: methodological issuesCurrent Opinion in Neurology, 18
-
O. Ullrich, K. Merker, Johanna Timm, S. Tauber (2007)
Immune control by endocannabinoids — New mechanisms of neuroprotection?Journal of Neuroimmunology, 184
-
I. Kim, Eun Kim, H. Nam, Mi Chin, Y. Moon, M. Oh, U. Yeo, S. Song, Jung Kim, M. Uhm, N. Beck, D. Jin (1999)
Activating Mutation of GSα in McCune-Albright Syndrome Causes Skin Pigmentation by Tyrosinase Gene Activation on Affected MelanocytesHormone Research in Paediatrics, 52
-
Sehyun Kim, S. Liva, M. Dalal, M. Verity, R. Voskuhl (1999)
Estriol ameliorates autoimmune demyelinating diseaseNeurology, 52
-
G. Comi, M. Filippi, F. Barkhof, L. Durelli, G. Edan, Ó. Fernández, H. Hartung, P. Seeldrayers, P. Sørensen, M. Rovaris, V. Martinelli, O. Hommes (2001)
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised studyThe Lancet, 357
-
E. Reinke, Matthew Johnson, Changying Ling, J. Karman, JangEun Lee, J. Weinstock, M. Sandor, Z. Fabry (2006)
Substance P receptor mediated maintenance of chronic inflammation in EAEJournal of Neuroimmunology, 180
-
A. Corcione, Simona Casazza, E. Ferretti, D. Giunti, Emanuela Zappia, A. Pistorio, C. Gambini, G. Mancardi, A. Uccelli, V. Pistoia (2004)
Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America, 101 30
-
Martin Weber, R. Hohlfeld, S. Zamvil (2007)
Mechanism of action of glatiramer acetate in treatment of multiple sclerosisNeurotherapeutics, 4
-
C Confavreux, P Saddier, J Grimaud (1996)
Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control studyNeurology, 46
-
H. Hartung, R. Gonsette, Nikolaus Konig, H. Kwiecinski, Andreas Guseo, S. Morrissey, H. Krapf, T. Zwingers (2002)
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trialThe Lancet, 360
-
H Wiendl, R Hohlfeld (2002)
Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trialsBioDrugs, 16
-
L. McCoy, Ikuo Tsunoda, R. Fujinami (2006)
Multiple sclerosis and virus induced immune responses: Autoimmunity can be primed by molecular mimicry and augmented by bystander activationAutoimmunity, 39
-
D. Pitt, P. Werner, C. Raine (2000)
Glutamate excitotoxicity in a model of multiple sclerosisNature Medicine, 6
-
J. Prineas, J. Prineas (1979)
Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord.Science, 203 4385
-
P. Villoslada, L. Barcellos, J. Río, A. Begovich, M. Tintoré, J. Sastre-Garriga, S. Baranzini, P. Casquero, S. Hauser, X. Montalban, J. Oksenberg (2002)
The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-βJournal of Neuroimmunology, 130
-
S. Waxman (2006)
Ions, energy and axonal injury: towards a molecular neurology of multiple sclerosis.Trends in molecular medicine, 12 5
-
M. Thangarajh, T. Masterman, J. Hillert, S. Moerk, R. Jonsson (2007)
A Proliferation‐inducing Ligand (APRIL) is Expressed by Astrocytes and is Increased in Multiple SclerosisScandinavian Journal of Immunology, 65
-
Paul Tak, R. Thurlings, C. Rossier, Ivan Nestorov, A. Dimic, V. Mircetić, Maureen Rischmueller, E. Nasonov, E. Shmidt, Paul Emery, Alain Munafo (2008)
Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.Arthritis and rheumatism, 58 1
-
F. Treumer, K. Zhu, R. Gläser, U. Mrowietz (2003)
Dimethylfumarate is a potent inducer of apoptosis in human T cells.The Journal of investigative dermatology, 121 6
-
C. Lock, G. Hermans, R. Pedotti, A. Brendolan, E. Schadt, H. Garren, A. Langer-Gould, S. Strober, B. Cannella, J. Allard, P. Klonowski, A. Austin, Nagin Lad, N. Kaminski, S. Galli, J. Oksenberg, C. Raine, R. Heller, L. Steinman (2002)
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitisNature Medicine, 8
-
H. Ulbrich, E. Eriksson, L. Lindbom (2003)
Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease.Trends in pharmacological sciences, 24 12
-
B. Cannella, C. Raine (1995)
The adhesion molecule and cytokine profile of multiple sclerosis lesionsAnnals of Neurology, 37
-
A. Ascherio, K. Munger (2007)
Environmental risk factors for multiple sclerosis. Part I: The role of infectionAnnals of Neurology, 61
-
H. Lassmann, W. Brück, C. Lucchinetti (2007)
The Immunopathology of Multiple Sclerosis: An OverviewBrain Pathology, 17
-
Paul O'Connor, Andrew Goodman, A. Willmer-Hulme, M. Libonati, Luanne Metz, R. Murray, William Sheremata, Timothy Vollmer, Lael Stone (2004)
Randomized multicenter trial of natalizumab in acute MS relapsesNeurology, 62
-
J. Gardell, P. Dazin, Janeen Islar, T. Menge, C. Genain, P. Lalive (2006)
Apoptotic effects of Human Herpesvirus-6A on glia and neurons as potential triggers for central nervous system autoimmunity.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 37 Suppl 1
-
D. Dyment, G. Ebers, A. Sadovnick (2004)
Genetics of multiple sclerosisThe Lancet Neurology, 3
-
R. Zivadinov (2007)
Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis?Neurology, 68
-
S. Mi, Robert Miller, X. Lee, M. Scott, Svetlane Shulag-Morskaya, Z. Shao, Jufang Chang, G. Thill, M. Lévesque, Mingdi Zhang, C. Hession, D. Sah, B. Trapp, Zhigang He, Vincent Jung, J. Mccoy, R. Pepinsky (2005)
LINGO-1 negatively regulates myelination by oligodendrocytesNature Neuroscience, 8
-
M. Matloubian, C. Lo, G. Cinamon, Matthew Lesneski, Ying Xu, V. Brinkmann, M. Allende, R. Proia, J. Cyster (2004)
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1Nature, 427
-
A. Bieber, S. Kerr, Moses Rodriguez (2003)
Efficient central nervous system remyelination requires T cellsAnnals of Neurology, 53
-
L. Kappos, D. Bates, G. Edan, M. Eraksoy, A. García‐Merino, N. Grigoriadis, H. Hartung, E. Havrdová, J. Hillert, R. Hohlfeld, M. Kremenchutzky, O. Lyon‐Caen, Ariel Miller, C. Pozzilli, M. Ravnborg, T. Saida, C. Sindic, K. Vass, D. Clifford, S. Hauser, E. Major, P. O'Connor, H. Weiner, M. Clanet, R. Gold, H. Hirsch, E. Radü, P. Sørensen, J. King (2007)
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoringThe Lancet Neurology, 10
-
I. Pirko, B. Ciric, Jeffrey Gamez, A. Bieber, A. Warrington, Aaron Johnson, D. Hanson, L. Pease, S. Macura, Moses Rodriguez (2004)
A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2‐weighted spinal cord MRI in a virus‐induced murine model of MSThe FASEB Journal, 18
-
L. Barcellos, J. Oksenberg, A. Begovich, E. Martin, S. Schmidt, E. Vittinghoff, D. Goodin, D. Pelletier, R. Lincoln, P. Bucher, A. Swerdlin, M. Pericak-Vance, J. Haines, S. Hauser (2003)
HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course.American journal of human genetics, 72 3
-
M. Girard, P. Duquette, W. Sibley (1993)
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.Neurology
-
F. Muiswinkel, H. Kuiperij (2005)
The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders.Current drug targets. CNS and neurological disorders, 4 3
-
Heinz Wiend, R. Hohlfeld (2012)
Therapeutic Approaches in Multiple SclerosisBioDrugs, 16
-
V. Yong, J. Wells, F. Giuliani, S. Casha, C. Power, Luanne Metz (2004)
The promise of minocycline in neurologyThe Lancet Neurology, 3
-
B. Weinshenker, B. Bass, G. Rice, J. Noseworthy, W. Carriere, J. Baskerville, G. Ebers (1989)
The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.Brain : a journal of neurology, 112 ( Pt 1)
-
G. Rice, M. Filippi, G. Comi (2000)
Cladribine and progressive MSNeurology, 54
-
Henry McFarland, F. Barkhof, Jack Antel, Dh Miller (2002)
The role of MRI as a surrogate outcome measure in multiple sclerosisMultiple Sclerosis, 8
-
S. Baranzini, Matthew Jeong, C. Butunoi, R. Murray, C. Bernard, J. Oksenberg (1999)
B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions.Journal of immunology, 163 9
-
H. Lipton, Zhiguo Liang, S. Hertzler, Kyung-No Son (2007)
A specific viral cause of multiple sclerosis: One virus, one diseaseAnnals of Neurology, 61
-
Y. Gilgun-Sherki, Hana Panet, E. Melamed, D. Offen (2003)
Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosisBrain Research, 989
-
E. Breij, B. Brink, R. Veerhuis, Christa Berg, R. Vloet, R. Yan, C. Dijkstra, P. Valk, L. Bö (2008)
Homogeneity of active demyelinating lesions in established multiple sclerosisAnnals of Neurology, 63
-
G. Giovannoni, G. Cutter, J. Lunemann, Roland Martin, C. Münz, S. Sriram, I. Steiner, M. Hammerschlag, C. Gaydos (2006)
Infectious causes of multiple sclerosisThe Lancet Neurology, 5
-
S. Schilling, S. Goelz, R. Linker, F. Luehder, R. Gold (2006)
Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltrationClinical & Experimental Immunology, 145
-
T. Korn, T. Magnus, K. Toyka, Stefan Jung (2004)
Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide— mechanisms independent of pyrimidine depletionJournal of Leukocyte Biology, 76
-
J. Haines, M. Ter-Minassian, A. Bazyk, J. Gusella, D. Kim, H. Terwedow, M. PericakVance, J. Rimmler, C. Haynes, A. Roses, A. Lee, B. Shaner, M. Menold, E. Seboun, R. Fitoussi, C. Gartioux, C. Reyes, F. Ribiérre, G. Gyapay, J. Weissenbach, S. Hauser, D. Goodkin, R. Lincoln, K. Usuku, A. García‐Merino, N. Gatto, S. Young, J. Oksenberg (1996)
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complexNature Genetics, 13
-
I. Casetta, G. Iuliano, G. Filippini (2007)
Azathioprine for multiple sclerosis.The Cochrane database of systematic reviews, 4
-
David Miller, S. Leary (2007)
Primary-progressive multiple sclerosisThe Lancet Neurology, 6
-
S. Dunn, S. Youssef, M. Goldstein, T. Prod'homme, Martin Weber, S. Zamvil, L. Steinman (2006)
Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatinThe Journal of Experimental Medicine, 203
-
Alexander Flügel, T. Berkowicz, T. Ritter, M. Labeur, D. Jenne, Zhaoxia Li, J. Ellwart, M. Willem, H. Lassmann, H. Wekerle (2001)
Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis.Immunity, 14 5
-
P. O'Connor, David Miller, K. Riester, Minhua Yang, M. Panzara, C. Dalton, K. Miszkiel, O. Khan, G. Rice, W. Sheremata (2005)
Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosisMultiple Sclerosis, 11
-
C. Confavreux, P. Saddier, J. Grimaud, T. Moreau, P. Adeleine, G. Aimard (1996)
Risk of cancer from azathioprine therapy in multiple sclerosisNeurology, 46
-
F. Zohren, Diamandis Toutzaris, Viola Klärner, H. Hartung, B. Kieseier, R. Haas (2008)
The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans.Blood, 111 7
-
R. Sergott, E. Frohman, R. Glanzman, A. Al-sabbagh (2007)
The role of optical coherence tomography in multiple sclerosis: Expert panel consensusJournal of the Neurological Sciences, 263
-
T. Menge, H. Hartung, O. Stüve (2005)
Statins — a cure-all for the brain?Nature Reviews Neuroscience, 6
-
Holger Babbe, Axel Roers, A. Waisman, H. Lassmann, N. Goebels, R. Hohlfeld, M. Friese, Roland Schröder, M. Deckert, S. Schmidt, R. Ravid, K. Rajewsky (2000)
Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain ReactionThe Journal of Experimental Medicine, 192
-
M. Jacobsen, Dun Zhou, S. Cepok, S. Nessler, M. Happel, Susanne Stei, B. Wilske, N. Sommer, B. Hemmer (2003)
Clonal accumulation of activated CD8+ T cells in the central nervous system during the early phase of neuroborreliosis.The Journal of infectious diseases, 187 6
-
L. Jacobs, D. Cookfair, R. Rudick, R. Herndon, J. Richert, A. Salazar, J. Fischer, D. Goodkin, C. Granger, J. Simon, J. Alam, D. Bartoszak, D. Bourdette, J. Braiman, C. Brownscheidle, M. Coats, S. Cohan, D. Dougherty, R. Kinkel, M. Mass, F. Munschauer, R. Priore, P. Pullicino, B. Scherokman, B. Weinstock-Guttman, R. Whitham (1996)
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 39
-
S. Gregory, S. Schmidt, P. Seth, J. Oksenberg, J. Hart, A. Prokop, S. Caillier, M. Ban, A. Goris, L. Barcellos, R. Lincoln, J. McCauley, S. Sawcer, D. Compston, B. Dubois, S. Hauser, M. Garcia-Blanco, M. Pericak-Vance, J. Haines (2007)
Interleukin 7 receptor α chain ( IL7R ) shows allelic and functional association with multiple sclerosisNature Genetics, 39
-
M. Craner, J. Newcombe, J. Black, C. Hartle, M. Cuzner, S. Waxman (2004)
Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger.Proceedings of the National Academy of Sciences of the United States of America, 101 21
-
C. Brunmark, A. Runström, L. Ohlsson, B. Sparre, T. Brodin, M. Åström, G. Hedlund (2002)
The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitisJournal of Neuroimmunology, 130
-
Lawrence Jacobs, Roy Beck, J. Simon, R. Kinkel, C. Brownscheidle, T. Murray, N. Simonian, P. Slasor, Alfred Sandrock (2000)
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.The New England journal of medicine, 343 13
-
R. Hohlfeld, M. Kerschensteiner, E. Meinl (2007)
Dual role of inflammation in CNS diseaseNeurology, 68
-
Roy Beck, P. Cleary, J. Trobe, D. Kaufman, M. Kupersmith, D. Paty, C. Brown (1993)
The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group.The New England journal of medicine, 329 24
-
J. Archelos, J. Trotter, S. Previtali, B. Weissbrich, K. Toyka, H. Hartung (1998)
Isolation and characterization of an oligodendrocyte precursor–derived B‐cell epitope in multiple sclerosisAnnals of Neurology, 43
-
Kenneth Smith (2007)
Sodium Channels and Multiple Sclerosis: Roles in Symptom Production, Damage and TherapyBrain Pathology, 17
-
(1999)
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis GroupNeurology, 53
-
D. Hafler, Alastair Compston, S. Sawcer, E. Lander, M. Daly, P. Jager, P. Bakker, S. Gabriel, D. Mirel, A. Ivinson, M. Pericak-Vance, S. Gregory, J. Rioux, J. McCauley, J. Haines, L. Barcellos, B. Cree, J. Oksenberg, S. Hauser (2007)
Risk alleles for multiple sclerosis identified by a genomewide study.The New England journal of medicine, 357 9
-
(1992)
Multiple sclerosis in 54 twinships: concordance rate is independent of zygosityAnn Neurol, 32
-
H. Wiendl, B. Kieseier, Robert Weissert, H. Mylius, U. Pichlmeier, H. Hartung, A. Melms, W. Kuker, M. Weller (2007)
Treatment of active secondary progressive multiple sclerosis with treosulfanJournal of Neurology, 254
-
(1998)
Randomised double-blind placebo-controlled study of interferon beta-la in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-la Subcutaneously in Multiple Sclerosis) Study GroupLancet, 352
-
V. Strand, F. Breedveld, J. Smolen, P. Emery, J. Kalden, P. Riel, M. Dougados (2004)
The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy.The Journal of rheumatology. Supplement, 71
-
J. Sipe, J. Romine, J. Koziol, R. McMillan, J. Zyroff, E. Beutler (1994)
Cladribine in treatment of chronic progressive multiple sclerosisThe Lancet, 344
-
H Krapf, SP Morrissey, O Zenker (2005)
Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trialNeurology, 65
-
S. Cepok, B. Rosche, V. Grummel, Friederike Vogel, Dun Zhou, Joachim Sayn, N. Sommer, H. Hartung, B. Hemmer (2005)
Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosisBrain, 128
-
M. Sospedra, Roland Martin (2005)
Immunology of multiple sclerosis.Annual review of immunology, 23
-
A. Bar-Or, P. Calabresi, D. Arnold, C. Markowitz, S. Shafer, L. Kasper, E. Waubant, S. Gazda, R. Fox, M. Panzara, N. Sarkar, S. Agarwal, Craig Smith (2008)
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trialAnnals of Neurology, 63
-
B. Oosten, M. Lai, S. Hodgkinson, F. Barkhof, D. Miller, I. Moseley, A. Thompson, P. Rudge, A. McDougall, J. McLeod, H. Adèr, C. Polman (1997)
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trialNeurology, 49
-
J. Berger, I. Koralnik (2005)
Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.The New England journal of medicine, 353 4
-
W. Hickey (2001)
Basic principles of immunological surveillance of the normal central nervous systemGlia, 36
-
RW Beck, PA Cleary, JD Trobe (1993)
The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosisThe Optic Neuritis Study Group. N Engl J Med, 329
-
B. Stankoff, Emmanuelle Waubant, Christian Confavreux, Gilles Edan, M. Debouverie, Lucien Rumbach, Thibault Moreau, Jean Pelletier, C. Lubetzki, M. Clanet (2005)
Modafinil for fatigue in MSNeurology, 64
-
S. Youssef, O. Stüve, J. Patarroyo, P. Ruiz, Jennifer Radosevich, E. Hur, Manuel Bravo, D. Mitchell, R. Sobel, L. Steinman, S. Zamvil (2002)
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune diseaseNature, 420
-
L. Madsen, E. Andersson, L. Jansson, M. Krogsgaard, C. Andersen, J. Engberg, J. Strominger, A. Svejgaard, J. Hjorth, R. Holmdahl, K. Wucherpfennig, L. Fugger (1999)
A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptorNature Genetics, 23
-
B Bielekova, N Richert, T Howard (2004)
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon betaProc Natl Acad Sci US A, 101
-
E. Beutler, J. Sipe, J. Romine, J. Koziol, R. McMillan, J. Zyroff (1996)
The treatment of chronic progressive multiple sclerosis with cladribine.Proceedings of the National Academy of Sciences of the United States of America, 93 4
-
Yufen Qin, Pierre Duquette, Yiping Zhang, Pierre Talbot, Robin Poole, J. Antel (1998)
Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis.The Journal of clinical investigation, 102 5
-
E. Salvatore, V. Morra, Guiseppe Orefice, G. Birnbaum, B. Cree, I. Altafullah, A. Reder (2008)
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosisNeurology, 71
-
NF Kalkers, F. Barkhof, E. Bergers, R. Schijndel, C. Polman (2002)
The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot studyMultiple Sclerosis, 8
-
J. Sedgwick, D. Mason (1986)
The mechanism of inhibition of experimental allergic encephalomyelitis in the rat by monoclonal antibody against CD4Journal of Neuroimmunology, 13
-
T. Yednock, C. Cannon, L. Fritz, F. Sánchez‐Madrid, L. Steinman, N. Karin (1992)
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrinNature, 356
-
T. Rhen, J. Cidlowski (2005)
Antiinflammatory action of glucocorticoids--new mechanisms for old drugs.The New England journal of medicine, 353 16
-
G. Rosati (2001)
The prevalence of multiple sclerosis in the world: an updateNeurological Sciences, 22
-
M. Dall'era, E. Chakravarty, D. Wallace, M. Genovese, M. Weisman, A. Kavanaugh, K. Kalunian, P. Dhar, E. Vincent, C. Peña-Rossi, D. Wofsy (2007)
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.Arthritis and rheumatism, 56 12
-
J. Browning (2006)
B cells move to centre stage: novel opportunities for autoimmune disease treatmentNature Reviews Drug Discovery, 5
-
M. Goldacre, V. Seagroatt, D. Yeates, E. Acheson (2004)
Skin cancer in people with multiple sclerosis: a record linkage studyJournal of Epidemiology and Community Health, 58
-
C. Trebst, M. Stangel (2006)
Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis.Current pharmaceutical design, 12 2
-
G. Krishnamoorthy, H. Lassmann, H. Wekerle, A. Holz (2006)
Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation.The Journal of clinical investigation, 116 9
-
Songli Wang, A. Sdrulla, G. Disibio, Gay Bush, D. Nofziger, C. Hicks, G. Weinmaster, B. Barres (1998)
Notch Receptor Activation Inhibits Oligodendrocyte DifferentiationNeuron, 21
-
David Miller, O. Khan, W. Sheremata, L. Blumhardt, G. Rice, M. Libonati, A. Willmer-Hulme, C. Dalton, K. Miszkiel, P. O'Connor (2003)
A controlled trial of natalizumab for relapsing multiple sclerosis.The New England journal of medicine, 348 1
-
H. Ochi, Michal Abraham, H. Ishikawa, D. Frenkel, Kaiyong Yang, A. Basso, H. Wu, M. Chen, R. Gandhi, Ariel Miller, R. Maron, H. Weiner (2006)
Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25−LAP+ T cellsNature Medicine, 12
-
V. Wee, Yong, Wee Yong (2002)
Differential mechanisms of action of interferon-β and glatiramer acetate in MSNeurology, 59
-
R. Eisenberg, D. Albert (2006)
B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosusNature Clinical Practice Rheumatology, 2
-
S. Mi, Bing Hu, Kyungmin Hahm, Yingpeng Luo, E. Hui, Q. Yuan, Wai-Man Wong, Li Wang, Huanxing Su, Tak-Ho Chu, Jiasong Guo, Wenming Zhang, K. So, B. Pepinsky, Z. Shao, Christilyn Graff, E. Garber, Vincent Jung, E. Wu, Wutian Wu (2007)
LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitisNature Medicine, 13
-
N. Scolding, R. Franklin (1997)
Remyelination in demyelinating disease.Bailliere's clinical neurology, 6 3
-
S. Schimrigk, Nils Brune, K. Hellwig, C. Lukas, B. Bellenberg, M. Rieks, V. Hoffmann, D. Pöhlau, H. Przuntek (2006)
Oral fumaric acid esters for the treatment of active multiple sclerosis: an open‐label, baseline‐controlled pilot studyEuropean Journal of Neurology, 13
-
D. Feinstein, E. Galea, V. Gavrilyuk, C. Brosnan, C. Whitacre, Lucia Dumitrescu-Ozimek, G. Landreth, H. Pershadsingh, G. Weinberg, M. Heneka (2002)
Peroxisome proliferator‐activated receptor‐γ agonists prevent experimental autoimmune encephalomyelitisAnnals of Neurology, 51
-
N. Huntington, R. Tomioka, Chelsea Clavarino, Anne Chow, D. Liñares, P. Mañá, J. Rossjohn, T. Cachero, Fang Qian, S. Kalled, C. Bernard, H. Reid (2006)
A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses.International immunology, 18 10
-
R. Kapoor, M. Davies, P. Blaker, Sue Hall, Kenneth Smith (2003)
Blockers of sodium and calcium entry protect axons from nitric oxide‐mediated degenerationAnnals of Neurology, 53
-
J. Tzartos, M. Friese, M. Craner, J. Palace, J. Newcombe, M. Esiri, L. Fugger (2008)
Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis.The American journal of pathology, 172 1
-
J. Black, Shujun Liu, B. Hains, C. Saab, S. Waxman (2006)
Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE.Brain : a journal of neurology, 129 Pt 12
-
B. Schütz, J. Reimann, Lucia Dumitrescu-Ozimek, K. Kappes-Horn, G. Landreth, B. Schürmann, A. Zimmer, M. Heneka (2005)
The Oral Antidiabetic Pioglitazone Protects from Neurodegeneration and Amyotrophic Lateral Sclerosis-Like Symptoms in Superoxide Dismutase-G93A Transgenic MiceThe Journal of Neuroscience, 25
-
L. Kappos (1998)
Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosisThe Lancet, 352
-
A. Coles, A. Cox, E. Page, Joanne Jones, S. Trip, J. Deans, S. Seaman, David Miller, G. Hale, H. Waldmann, D. Compston (2005)
The window of therapeutic opportunity in multiple sclerosisJournal of Neurology, 253
-
R. Rudick, W. Stuart, P. Calabresi, C. Confavreux, S. Galetta, E. Radue, F. Lublin, B. Weinstock-Guttman, D. Wynn, F. Lynn, M. Panzara, A. Sandrock (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.The New England journal of medicine, 354 9
-
D. Centonze, M. Bari, S. Rossi, C. Prosperetti, R. Furlan, F. Fezza, V. Chiara, L. Battistini, G. Bernardi, S. Bernardini, G. Martino, M. Maccarrone (2007)
The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis.Brain : a journal of neurology, 130 Pt 10
-
A. Lovett-racke, Rehana Hussain, Sara Northrop, Judy Choy, A. Rocchini, Lela Matthes, J. Chavis, A. Diab, P. Drew, M. Racke (2004)
Peroxisome Proliferator-Activated Receptor α Agonists as Therapy for Autoimmune Disease1The Journal of Immunology, 172
-
G. Owens, A. Ritchie, M. Burgoon, R. Williamson, J. Corboy, D. Gilden (2003)
Single-Cell Repertoire Analysis Demonstrates that Clonal Expansion Is a Prominent Feature of the B Cell Response in Multiple Sclerosis Cerebrospinal Fluid 1The Journal of Immunology, 171
-
R. Armstrong, R. Barker (2001)
Neurodegeneration: a failure of neuroregeneration?The Lancet, 358
-
Ansi Chang, W. Tourtellotte, R. Rudick, B. Trapp (2002)
Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis.The New England journal of medicine, 346 3
-
Arnason Bgw., G. Jacobs, M. Hanlon, B. Clay, Noronha Abc., A. Auty, B. Davis, A. Nath, J. Bouchard, C. Bélanger, F. Gosselin, M. Thibault, P. Duquette, P. Bourgoin, R. Dubois, M. Girard, G. Ebers, Rice Gpa., M. Vandervoort, G. Francis, L. Duncan, Y. Lapierre, M. Freedman, S. Christie, H. Rabinovitch, D. Patry, W. Murphy, S. Peters, S. McGuiness, T. Murray, V. Bhan, C. Maxner, R. Dorpe, J. Oger, J. Nelson, W. Morrison, N. Bogle, S. Beall, G. Vorobeychick, A. Hiltbrunner, J. Bock, W. Lesslauer, Li Dkb., D. Paty, Guojun Zhao, Grp Lmss., Grp Ubcmsmria. (1999)
TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter studyNeurology, 77
-
(2007)
Induction of Antigen-Specific Tolerance in Multiple Sclerosis After Immunization With DNA Encoding Myelin Basic Protein in a Randomized, Placebo-Controlled Phase 1/2 Trial -
M. Friese, L. Jensen, N. Willcox, L. Fugger (2006)
Humanized mouse models for organ-specific autoimmune diseases.Current opinion in immunology, 18 6
-
O. Stüve, S. Cepok, B. Elias, A. Saleh, H. Hartung, B. Hemmer, B. Kieseier (2005)
Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.Archives of neurology, 62 10
-
A. Paolillo, A. Coles, P. Molyneux, M. Gawne-Cain, D. MacManus, G. Barker, D. Compston, D. Miller (1999)
Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1HNeurology, 53
-
H. McFarland (2008)
The B cell--old player, new position on the team.The New England journal of medicine, 358 7
-
E. Klawiter, A. Cross (2007)
B cells: No longer the nondominant arm of multiple sclerosisCurrent Neurology and Neuroscience Reports, 7
-
H. Harris (2007)
Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab.Rheumatology, 47 2
-
E. Ubogu, M. Cossoy, R. Ransohoff (2006)
The expression and function of chemokines involved in CNS inflammation.Trends in pharmacological sciences, 27 1
-
M Charcot (1868)
Histologie de la sclerose on plaqueGaz Hop Paris, 141
-
E. Frohman, M. Racke, C. Raine (2006)
Multiple sclerosis--the plaque and its pathogenesis.The New England journal of medicine, 354 9
-
G. Comi, A. Pulizzi, M. Rovaris, O. Abramsky, T. Arbizu, A. Boiko, R. Gold, E. Havrdová, S. Komoly, K. Selmaj, B. Sharrack, M. Filippi (2008)
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyThe Lancet, 371
-
M. Webb, C. Tham, F. Lin, Karen Lariosa-Willingham, N. Yu, J. Hale, S. Mandala, J. Chun, T. Rao (2004)
Sphingosine 1-phosphate receptor agonists attenuate relapsing–remitting experimental autoimmune encephalitis in SJL miceJournal of Neuroimmunology, 153
-
R. Magliozzi, O. Howell, A. Vora, B. Serafini, R. Nicholas, M. Puopolo, R. Reynolds, F. Aloisi (2007)
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.Brain : a journal of neurology, 130 Pt 4
-
G. Cavaletti, E. Cavalletti, L. Crippa, E. Luccio, N. Oggioni, B. Mazzanti, T. Biagioli, F. Sala, V. Sala, M. Frigo, S. Rota, E. Tagliabue, L. Stanzani, S. Galbiati, R. Rigolio, C. Zoia, G. Tredici, P. Perseghin, M. Dassi, P. Riccio, F. Lolli (2004)
Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitisJournal of Neuroimmunology, 151
-
S. Kuokkanen, M. Sundvall, J. Terwilliger, P. Tienari, J. Wikström, R. Holmdahl, U. Pettersson, L. Peltonen (1996)
A putative vulnerability locus to multiple sclerosis maps to 5p14–p12 in a region syntenic to the murine locus Eae2Nature Genetics, 13
-
Robert Fox, Elizabeth Fisher, R. Rudick (2002)
Disease modifying therapies in multiple sclerosis.Neurology, 59 3
-
G Comi, M Filippi, JS Wolinsky (2001)
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging: measured disease activity and burden in patients with relapsing multiple sclerosisEuropean/Canadian Glatiramer Acetate Study Group. Ann Neurol, 49
-
B. Bielekova, N. Richert, T. Howard, G. Blevins, S. Markovic-Plese, J. McCartin, J. Frank, J. Würfel, J. Ohayon, T. Waldmann, H. McFarland, Roland Martin (2004)
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.Proceedings of the National Academy of Sciences of the United States of America, 101 23
-
B. Oosten, L. Truyen, F. Barkhof, C. Polman (1998)
Choosing Drug Therapy for Multiple SclerosisDrugs, 56
-
R. Dutta, B. Trapp (2007)
Pathogenesis of axonal and neuronal damage in multiple sclerosisNeurology, 68
-
P. Calabresi, N. Fields, H. Maloni, A. Hanham, J. Carlino, J. Moore, Michael Levin, S. Dhib-Jalbut, L. Tranquill, H. Austin, H. McFarland, M. Racke (1998)
Phase 1 trial of transforming growth factor beta 2 in chronic progressive MSNeurology, 51
-
B. Weinshenker, B. Bass, S. Karlik, G. Ebers, G. Rice (1991)
An open trial of OKT3 in patients with multiple sclerosisNeurology, 41
-
J. Oger (2007)
Immunosuppression: Promises and failuresJournal of the Neurological Sciences, 259
-
C. Polman, F. Barkhof, M. Sandberg-wollheim, A. Linde, O. Nordle, T. Nederman (2005)
Treatment with laquinimod reduces development of active MRI lesions in relapsing MSNeurology, 64
-
K. Gijbels, Richard Galardy, Lawrence Steinman (1994)
Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases.The Journal of clinical investigation, 94 6
-
N. Nielsen, K. Rostgaard, S. Rasmussen, N. Koch-Henriksen, H. Storm, M. Melbye, H. Hjalgrim (2006)
Cancer risk among patients with multiple sclerosis: A population‐based register studyInternational Journal of Cancer, 118
-
B. Bielekova, B. Goodwin, N. Richert, I. Cortese, T. Kondo, G. Afshar, B. Gran, J. Eaton, J. Antel, J. Frank, H. McFarland, Roland Martin (2000)
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligandNature Medicine, 6
-
PW O'Connor, A Goodman, AJ Willmer-Hulme (2004)
Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effectsNeurology, 62
-
S. Hauser, E. Waubant, D. Arnold, T. Vollmer, J. Antel, R. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S. Agarwal, A. Langer-Gould, Craig Smith (2008)
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.The New England journal of medicine, 358 7
-
R. Gold, A. Jawad, D. Miller, D. Henderson, A. Fassas, Walter Fierz, H. Hartung (2007)
Expert opinion: Guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapiesJournal of Neuroimmunology, 187
-
V. Yong, F. Giuliani, M. Xue, A. Bar-Or, L. Metz (2007)
Experimental models of neuroprotection relevant to multiple sclerosisNeurology, 68
-
O. Neuhaus, B. Kieseier, H. Hartung (2006)
Therapeutic role of mitoxantrone in multiple sclerosis.Pharmacology & therapeutics, 109 1-2
-
Robert Weissert, H. Wiendl, H. Pfrommer, M. Storch, M. Weller (2003)
Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytesJournal of Neuroimmunology, 144
-
Y. Blanco, A. Saiz, E. Carreras, F. Graus (2005)
Autologous haematopoietic-stem-cell transplantation for multiple sclerosisThe Lancet Neurology, 4
-
C. Markowitz (2007)
Interferon-betaNeurology, 68
-
M. Krumbholz, D. Theil, T. Derfuss, A. Rosenwald, F. Schrader, C. Monoranu, S. Kalled, D. Hess, B. Serafini, F. Aloisi, H. Wekerle, R. Hohlfeld, E. Meinl (2005)
BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphomaThe Journal of Experimental Medicine, 201
-
C. Vanderlugt, S. Miller (2002)
Epitope spreading in immune-mediated diseases: implications for immunotherapyNature Reviews Immunology, 2
-
O. Stüve, J. Bennett, B. Hemmer, H. Wiendl, M. Racke, A. Bar-Or, Wei Hu, R. Zivadinov, Martin Weber, S. Zamvil, M. Pacheco, T. Menge, H. Hartung, B. Kieseier, E. Frohman (2008)
Pharmacological Treatment of Early Multiple SclerosisDrugs, 68
-
TA Yednock, C Cannon, LC Fritz (1992)
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrinNature, 356
-
C. Polman, P. O'connor, E. Havrdová, M. Hutchinson, L. Kappos, David Miller, J. Phillips, F. Lublin, G. Giovannoni, A. Wajgt, M. Toal, F. Lynn, M. Panzara, A. Sandrock (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.The New England journal of medicine, 354 9
-
D. Teitelbaum, A. Meshorer, T. Hirshfeld, R. Arnon, M. Sela (1971)
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptideEuropean Journal of Immunology, 1
-
L. Kappos, J. Antel, G. Comi, X. Montalban, P. O'Connor, C. Polman, T. Haas, A. Korn, G. Karlsson, E. Radue (2006)
Oral fingolimod (FTY720) for relapsing multiple sclerosis.The New England journal of medicine, 355 11
-
B. Bielekova, M. Catálfamo, Susan Reichert-Scrivner, Amy Packer, M. Cerná, T. Waldmann, H. McFarland, P. Henkart, Roland Martin (2006)
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America, 103 15
-
Moses Rodriguez (2007)
Effectors of Demyelination and Remyelination in the CNS: Implications for Multiple SclerosisBrain Pathology, 17
-
R. Ransohoff, P. Kivisäkk, G. Kidd (2003)
Three or more routes for leukocyte migration into the central nervous systemNature Reviews Immunology, 3
-
Stephen Miller, J. Olson, J. Croxford (2001)
Multiple pathways to induction of virus-induced autoimmune demyelination: lessons from Theiler's virus infection.Journal of autoimmunity, 16 3
-
J. Kesselring, S. Beer (2005)
Symptomatic therapy and neurorehabilitation in multiple sclerosisThe Lancet Neurology, 4
-
MJ Tullman, RJ Oshinsky, Fd, Lublin, Gr, Cutter (2004)
Clinical characteristics of progressive relapsing multiple sclerosisMultiple Sclerosis, 10
-
G. Comi (2008)
Is it clinically relevant to repair focal multiple sclerosis lesions?Journal of the Neurological Sciences, 265
-
G. Tran, N. Carter, Xiao-Yan He, Timothy Spicer, Karen Plain, M. Nicolls, B. Hall, S. Hodgkinson (2001)
Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4.International immunology, 13 9
-
M. Clerico, G. Contessa, L. Durelli (2007)
Interferon-β1a for the treatment of multiple sclerosisExpert Opinion on Biological Therapy, 7
-
L. Klotz, Martina Schmidt, T. Giese, M. Sastre, P. Knolle, T. Klockgether, M. Heneka (2005)
Proinflammatory Stimulation and Pioglitazone Treatment Regulate Peroxisome Proliferator-Activated Receptor γ Levels in Peripheral Blood Mononuclear Cells from Healthy Controls and Multiple Sclerosis PatientsThe Journal of Immunology, 175
-
(1993)
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I, clinical results of a multicenter, randomized, double-blind, placebocontrolled trialNeurology, 43
-
L. Bonanni, Astrid Thomas, M. Onofrj (2005)
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB ConsortiumNeurology, 66
-
F. Durr, R. Wallace, R. Citarella (1983)
Molecular and biochemical pharmacology of mitoxantrone.Cancer treatment reviews, 10 Suppl B
-
T. Kopadze, T. Dehmel, H. Hartung, O. Stüve, B. Kieseier (2006)
Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis.Archives of neurology, 63 11
-
J. Rose, H. Watt, A. White, N. Carlson (2004)
Treatment of multiple sclerosis with an anti–interleukin‐2 receptor monoclonal antibodyAnnals of Neurology, 56
-
O Stuve, CM Marra, A Bar-Or (2006)
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosisArch Neurol, 63
-
G. Pryce, Z. Ahmed, D. Hankey, S. Jackson, J. Croxford, J. Pocock, C. Ledent, A. Petzold, A. Thompson, G. Giovannoni, M. Cuzner, D. Baker (2003)
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.Brain : a journal of neurology, 126 Pt 10
-
J. Archelos, M. Storch, H. Hartung (2000)
The role of B cells and autoantibodies in multiple sclerosisAnnals of Neurology, 47
-
A. Pascual, M. Martínez-Bisbal, I. Boscá, C. Valero, F. Coret, B. Martínez-Granados, L. Martí-Bonmatí, A. Mir, B. Celda, B. Casanova (2007)
Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosisNeurology, 69
-
K. Johnson, B. Brooks, Jeffrey Cohen, C. Ford, Jill Goldstein, R. Lisak, L. Myers, H. Panitch, J. Rose, R. Schiffer, T. Vollmer, L. Weiner, J. Wolinsky (1995)
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 45
-
O. Neuhaus, H. Wiendl, B. Kieseier, J. Archelos, B. Hemmer, O. Stüve, H. Hartung (2005)
Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitroJournal of Neuroimmunology, 168
-
N. Popovic, A. Schubart, B. Goetz, Su-Chun Zhang, C. Linington, I. Duncan (2002)
Inhibition of autoimmune encephalomyelitis by a tetracyclineAnnals of Neurology, 51
-
Nicola Stefano, Paul Matthews, Liqun Fu, S. Narayanan, J. Stanley, G. Francis, J. Antel, D. Arnold (1998)
Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study.Brain : a journal of neurology, 121 ( Pt 8)
-
D. Bechtold, Sandra Miller, A. Dawson, Yue-Ji Sun, R. Kapoor, D. Berry, Kenneth Smith (2006)
Axonal protection achieved in a model of multiple sclerosis using lamotrigineJournal of Neurology, 253
-
J. Killestein, N. Kalkers, C. Polman (2005)
Glutamate inhibition in MS: The neuroprotective properties of riluzoleJournal of the Neurological Sciences, 233
-
O. Aktas, T. Prozorovski, A. Smorodchenko, N. Savaskan, R. Lauster, P. Kloetzel, C. Infante-Duarte, S. Brocke, F. Zipp (2004)
Green Tea Epigallocatechin-3-Gallate Mediates T Cellular NF-κB Inhibition and Exerts Neuroprotection in Autoimmune Encephalomyelitis1The Journal of Immunology, 173
-
O. Stüve, S. Youssef, Martin Weber, S. Nessler, H.-Christian Büdingen, B. Hemmer, T. Prod'homme, R. Sobel, L. Steinman, S. Zamvil (2006)
Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.The Journal of clinical investigation, 116 4
-
E. Meinl, M. Krumbholz, R. Hohlfeld (2006)
B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulationAnnals of Neurology, 59
-
Monica Colombo, M. Dono, P. Gazzola, S. Roncella, A. Valetto, N. Chiorazzi, G. Mancardi, M. Ferrarini (2000)
Accumulation of Clonally Related B Lymphocytes in the Cerebrospinal Fluid of Multiple Sclerosis Patients1The Journal of Immunology, 164
-
JL Haines, M Minassian, A Bazyk (1996)
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complexThe Multiple Sclerosis Genetics Group. Nat Genet, 13
-
P. Patrikios, C. Stadelmann, A. Kutzelnigg, H. Rauschka, M. Schmidbauer, H. Laursen, P. Sørensen, W. Brück, C. Lucchinetti, H. Lassmann (2006)
Remyelination is extensive in a subset of multiple sclerosis patients.Brain : a journal of neurology, 129 Pt 12
-
R. Franklin (2002)
Why does remyelination fail in multiple sclerosis?Nature Reviews Neuroscience, 3
-
H. Garren, W. Robinson, E. Krasulová, E. Havrdová, Č. Nadj, K. Selmaj, J. Losy, Ilinka Nadj, E. Radue, B. Kidd, Jill Gianettoni, Karen Tersini, P. Utz, F. Valone, L. Steinman (2008)
Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosisAnnals of Neurology, 63
-
R. Gold, C. Linington, H. Lassmann (2006)
Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research.Brain : a journal of neurology, 129 Pt 8
-
C. Vaney, M. Heinzel‐Gutenbrunner, P. Jobin, F. Tschopp, B. Gattlen, U. Hagen, M. Schnelle, M. Reif (2004)
Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover studyMultiple Sclerosis, 10
-
Joanne Jones, A. Coles (2007)
Campath-1H Treatment of Multiple SclerosisNeurodegenerative Diseases, 5
-
A. Munafo, A. Priestley, I. Nestorov, J. Visich, M. Rogge (2007)
Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteersEuropean Journal of Clinical Pharmacology, 63
-
T. Kuhlmann, Gueanelle Lingfeld, A. Bitsch, J. Schuchardt, W. Brück (2002)
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.Brain : a journal of neurology, 125 Pt 10
-
T. Vollmer, L. Key, V. Durkalski, W. Tyor, J. Corboy, S. Markovic-Plese, J. Preiningerova, M. Rizzo, I. Singh (2004)
Oral simvastatin treatment in relapsing-remitting multiple sclerosisThe Lancet, 363
-
LD Jacobs, RW Beck, JH Simon (2000)
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosisCHAMPS Study Group. N Engl J Med, 343
-
D. Miller, KS Sanborn, J. Katzmann, M. Rodriguez (1994)
Monoclonal autoantibodies promote central nervous system repair in an animal model of multiple sclerosis, 14
-
N Tubridy, PO Behan, R Capildeo (1999)
The effect of anti-alpha4 integrin antibody on brain lesion activity in MSUK Antegren Study Group. Neurology, 53
-
B. Hemmer, E. Frohman, H. Hartung, O. Stüve (2006)
Central nervous system infections - a potential complication of systemic immunotherapy.Current opinion in neurology, 19 3
-
O. Stüve, Christina Marra, P. Cravens, Mahendra Singh, Wei Hu, A. Lovett-racke, Nancy Monson, J. Phillips, Jan Tervaert, Richard Nash, H. Hartung, B. Kieseier, M. Racke, E. Frohman, B. Hemmer (2007)
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.Archives of neurology, 64 2
-
H. Weiner (2004)
Immunosuppressive treatment in multiple sclerosisJournal of the Neurological Sciences, 223
-
D. Tennakoon, R. Mehta, Sterling Ortega, V. Bhoj, M. Racke, N. Karandikar (2006)
Therapeutic Induction of Regulatory, Cytotoxic CD8+ T Cells in Multiple Sclerosis1The Journal of Immunology, 176
-
F. Barkhof, W. Bruck, C. GROOT, E. Bergers, S. Hulshof, J. Geurts, C. Polman, P. Valk (2003)
Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance.Archives of neurology, 60 8
-
G. Ebers, Kim Kukay, D. Bulman, A. Sadovnick, G. Rice, C. Anderson, H. Armstrong, K. Cousin, R. Bell, W. Hader, D. Paty, S. Hashimoto, J. Oger, P. Duquette, S. Warren, T. Gray, P. O'Connor, A. Nath, A. Auty, L. Metz, G. Francis, J. Paulseth, T. Murray, W. Pryse-Phillips, R. Nelson, M. Freedman, D. Brunet, J. Bouchard, D. Hinds, N. Risch (1996)
A full genome search in multiple sclerosisNature Genetics, 13
-
A. Sadovnick, G. Ebers, D. Dyment, Neil Risch (1996)
Evidence for genetic basis of multiple sclerosisThe Lancet, 347
-
R. Rudick, Jeffrey Cohen, Bianca Weinstock-Guttman, R. Kinkel, R. Ransohoff (1997)
Management of multiple sclerosis.The New England journal of medicine, 337 22
-
H Ochi, M Abraham, H Ishikawa (2006)
Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+Nat Med, 12
-
T. Korn, K. Toyka, H. Hartung, Stefan Jung (2001)
Suppression of experimental autoimmune neuritis by leflunomide.Brain : a journal of neurology, 124 Pt 9
-
C Bozic, G Belcher, M Kooijmans-Coutinho (2008)
Natalizumab utilization and safety in patients with relapsing multiple sclerosis: updated results from TOUCH and TYGRIS [abstract]Neurology, 70
-
E. Bettelli, D. Baeten, A. Jäger, R. Sobel, V. Kuchroo (2006)
Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice.The Journal of clinical investigation, 116 9
-
H. Rosen, E. Goetzl (2005)
Sphingosine 1-phosphate and its receptors: an autocrine and paracrine networkNature Reviews Immunology, 5
-
AJ Coles, A Cox, E Page (2006)
The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapyJ Neurol, 253
-
B. Hemmer, J. Archelos, H. Hartung (2002)
New concepts in the immunopathogenesis of multiple sclerosisNature Reviews Neuroscience, 3
-
M. Racke, S. Dhib-Jalbut, B. Cannella, P. Albert, C. Raine, D. McFarlin (1991)
Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1.Journal of immunology, 146 9
-
H. Müller, S. Hofer, N. Kaneider, H. Neuwirt, B. Mosheimer, G. Mayer, G. Konwalinka, C. Heufler, M. Tiefenthaler (2005)
The immunomodulator FTY720 interferes with effector functions of human monocyte‐derived dendritic cellsEuropean Journal of Immunology, 35
-
C. Bjartmar, B. Trapp (2001)
Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequencesCurrent Opinion in Neurology, 14
-
V. Yong (2005)
Metalloproteinases: Mediators of Pathology and Regeneration in the CNSNature Reviews Neuroscience, 6
-
J. Wells, R. Hurlbert, M. Fehlings, V. Yong (2003)
Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice.Brain : a journal of neurology, 126 Pt 7
-
A. Boster, G. Edan, E. Frohman, A. Javed, O. Stuve, A. Tselis, H. Weiner, B. Weinstock-Guttman, O. Khan (2008)
Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinicianThe Lancet Neurology, 7
-
J. Gross, S. Dillon, S. Mudri, J. Johnston, A. Littau, R. Roque, M. Rixon, Ole Schou, K. Foley, H. Haugen, Susan McMillen, K. Waggie, Randy Schreckhise, K. Shoemaker, T. Vu, M. Moore, A. Grossman, C. Clegg (2001)
TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS.Immunity, 15 2
-
G. Comi, M. Filippi, J. Wolinsky (2001)
European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosisAnnals of Neurology, 49
-
DS Goodin, EM Frohman, GP Garmany (2002)
Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice GuidelinesNeurology, 58
-
C. Teunissen, C. Dijkstra, C. Polman (2005)
Biological markers in CSF and blood for axonal degeneration in multiple sclerosisThe Lancet Neurology, 4
-
V. Brinkmann, Michael Davis, C. Heise, R. Albert, S. Cottens, R. Hof, C. Bruns, E. Prieschl, T. Baumruker, P. Hiestand, C. Foster, M. Zollinger, K. Lynch (2002)
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors*The Journal of Biological Chemistry, 277
-
Moses Rodriguez, V. Lennon (1990)
Immunoglobulins promote remyelination in the central nervous systemAnnals of Neurology, 27
-
D. Merkler, Edit Horváth, W. Bruck, R. Zinkernagel, Juan Torre, D. Pinschewer (2006)
"Viral déjà vu" elicits organ-specific immune disease independent of reactivity to self.The Journal of clinical investigation, 116 5
-
Ph. Coles, F.R.C. Alastair, F.Med.Sci Compston, M. Selmaj, Sc.D Lake, M. Moran, David M.S.C.E., Kim Ph.D., B.Sc Tandon (2008)
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.The New England journal of medicine, 359 17
-
A. Warrington, A. Bieber, B. Ciric, L. Pease, V. Keulen, Moses Rodriguez (2007)
A recombinant human IgM promotes myelin repair after a single, very low doseJournal of Neuroscience Research, 85
-
V. Yong, Smriti Agrawal, David Stirling (2007)
Targeting MMPs in acute and chronic neurological conditionsNeurotherapeutics, 4
-
P. O'Connor, David Li, M. Freedman, A. Bar-Or, G. Rice, C. Confavreux, D. Paty, J. Stewart, R. Scheyer (2006)
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesNeurology, 66
-
L. Metz, Yunyan Zhang, M. Yeung, D. Patry, R. Bell, C. Stoian, V. Yong, S. Patten, P. Duquette, J. Antel, J. Mitchell (2004)
Minocycline reduces gadolinium‐enhancing magnetic resonance imaging lesions in multiple sclerosisAnnals of Neurology, 55
-
V. Brundula, N. Rewcastle, L. Metz, C. Bernard, V. Yong (2002)
Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis.Brain : a journal of neurology, 125 Pt 6
-
RG Ghalie, E. Mauch, G. Edan, H.-P. Hartung, RE Gonsette, S. Eisenmann, E. Page, MD Butine, DE Goodkin (2002)
A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosisMultiple Sclerosis, 8
-
Stefan Jung, K. Toyka, H. Hartung (1995)
Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2European Journal of Immunology, 25
-
W. Rastetter, A. Molina, C. White (2004)
Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.Annual review of medicine, 55
-
M. Koch, J. Mostert, J. Vries, J. Keyser (2006)
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesNeurology, 68
-
L. Kappos, D. Miller, D. MacManus, R. Gold, E. Havrdová, Limmroth, C. Polrnan, K. Schmierer, T. Yousry, M. Long, M. Eraksoy, E. Meluzínová, I. Rektor, G. O'neill (2006)
Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study -
O. Stüve, C. Marra, K. Jerome, L. Cook, P. Cravens, S. Cepok, E. Frohman, J. Phillips, G. Arendt, B. Hemmer, N. Monson, M. Racke (2006)
Immune surveillance in multiple sclerosis patients treated with natalizumabAnnals of Neurology, 59
-
N. Tubridy, P. Behan, R. Capildeo, A. Chaudhuri, R. Forbes, Clive Hawkins, R. Hughes, Jacqueline Palace, B. Sharrack, R. Swingler, C. Young, I. Moseley, D. MacManus, S. Donoghue, D. Miller (1999)
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.Neurology, 53 3
-
G. Martino, S. Pluchino (2006)
The therapeutic potential of neural stem cellsNature Reviews Neuroscience, 7
-
D. Avery, S. Kalled, J. Ellyard, C. Ambrose, S. Bixler, M. Thien, R. Brink, F. Mackay, P. Hodgkin, S. Tangye (2003)
BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.The Journal of clinical investigation, 112 2
-
R. Zabad, L. Metz, T. Todoruk, Yunyan Zhang, J. Mitchell, M. Yeung, D. Patry, R. Bell, V. Yong (2007)
The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot studyMultiple Sclerosis, 13
-
E. Pucci, Pedro Tato, R. D'amico, G. Giuliani, A. Solari, C. Taus (2007)
Amantadine for fatigue in multiple sclerosis.The Cochrane database of systematic reviews, 2
-
Karen Yao, S. Gagnon, N. Akhyani, Elizabeth Williams, J. Fotheringham, E. Frohman, O. Stuve, N. Monson, M. Racke, S. Jacobson (2008)
Reactivation of Human Herpesvirus-6 in Natalizumab Treated Multiple Sclerosis PatientsPLoS ONE, 3
-
H Wiendl, BC Kieseier, R Weissert (2007)
Treatment of active secondary progressive multiple sclerosis with treosulfanJ Neurol, 254
-
L. Calabrese, E. Molloy, Deren Huang, R. Ransohoff (2007)
Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease.Arthritis and rheumatism, 56 7
-
T. Berger, M. Reindl (2007)
Multiple sclerosis: Disease biomarkers as indicated by pathophysiologyJournal of the Neurological Sciences, 259
-
J. Sotelo, A. Martínez-Palomo, G. Ordoñez, B. Pineda (2008)
Varicella‐zoster virus in cerebrospinal fluid at relapses of multiple sclerosisAnnals of Neurology, 63
-
Smriti Agrawal, Lorraine Lau, V. Yong (2008)
MMPs in the central nervous system: where the good guys go bad.Seminars in cell & developmental biology, 19 1
-
CE Markowitz (2007)
Interferon-beta: mechanism of action and dosing issuesNeurology, 68
-
S Kim, SM Liva, MA Dalai (1999)
Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosisNeurology, 52
-
B. Trapp, J. Peterson, R. Ransohoff, R. Rudick, S. Mørk, L. Bø (1998)
Axonal transection in the lesions of multiple sclerosis.The New England journal of medicine, 338 5
- Publisher
- Springer Journals
- Copyright
- Copyright © 2008 by Adis Data Information BV
- Subject
- Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
- ISSN
- 0012-6667
- eISSN
- 1179-1950
- DOI
- 10.2165/0003495-200868170-00004
- pmid
- 19016573
- Publisher site
- See Article on Publisher Site
Abstract
Multiple sclerosis (MS) is a chronic autoimmune disease of the CNS. Currently, six medications are approved for immunmodulatory and immunosuppressive treatment of the relapsing disease course and secondary-progressive MS. In the first part of this review, the pathogenesis of MS and its current treatment options are discussed.
Journal
Drugs – Springer Journals
Published: Oct 15, 2012